---
title: "China National Accord Medicines Corporation Ltd. (000028.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000028.SZ.md"
symbol: "000028.SZ"
name: "China National Accord Medicines Corporation Ltd."
industry: "Health Care Distributors"
datetime: "2026-05-02T05:48:48.949Z"
locales:
  - [en](https://longbridge.com/en/quote/000028.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000028.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000028.SZ.md)
---

# China National Accord Medicines Corporation Ltd. (000028.SZ)

## Company Overview

China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company offers new and special drugs and medications for chronic diseases. It also provides traditional Chinese medicine, Western medicine, rehabilitation therapy, and various medical-related resources, as well as chemical drugs, OTC drugs, and health products.

| Item | Detail |
|------|--------|
| Industry | Health Care Distributors |
| Exchange | CN Market |
| Website | [www.szaccord.com.cn](https://www.szaccord.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-01T04:30:14.000Z

**Overall: C (0.47)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 8 / 24 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -0.86% |  |
| Net Profit YoY | 88.30% |  |
| P/B Ratio | 0.72 |  |
| Dividend Ratio | 1.49% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 13638532919.52 |  |
| Revenue | 72841206855.61 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.94% | C |
| Profit Margin | 1.50% | C |
| Gross Margin | 9.96% | E |
| Revenue YoY | -0.86% | D |
| Net Profit YoY | 88.30% | A |
| Total Assets YoY | -1.80% | D |
| Net Assets YoY | 3.84% | C |
| Cash Flow Margin | 47.52% | C |
| OCF YoY | -0.86% | D |
| Turnover | 1.47 | A |
| Gearing Ratio | 55.39% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - China National Accord Medicines Corporation Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-0.86%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "88.30%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.72",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.49%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "13638532919.52",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "72841206855.61",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.94%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "1.50%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "9.96%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-0.86%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "88.30%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-1.80%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.84%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "47.52%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-0.86%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "1.47",
          "rating": "A"
        },
        {
          "name": "Gearing Ratio",
          "value": "55.39%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 12.47 | 6/24 | 26.51 | 25.06 | 24.03 |
| PB | 0.72 | 2/24 | 0.79 | 0.78 | 0.76 |
| PS (TTM) | 0.19 | 5/24 | 0.20 | 0.19 | 0.19 |
| Dividend Yield | 1.49% | 13/24 | 1.48% | 1.44% | 1.42% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | HUADONG MEDICINE (000963.SZ) | B | C | A | B | C | B |
| 02 | SINOPHARM(CNCM LTD) (600511.SH) | C | C | A | C | C | B |
| 03 | TIBET PHARMA (600211.SH) | A | C | C | B | C | B |
| 04 | Shanghai Pharma (601607.SH) | C | C | E | A | C | C |
| 05 | GYBYS (600332.SH) | C | C | A | C | C | C |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-26T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Overweight | 1 | 20% |
| Sell | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.54 |
| Highest Target | 32.13 |
| Lowest Target | 19.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000028.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000028.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000028.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000028.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**